Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715012 · ClinicalTrials.gov registry record · Phase 2
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01715012 is a Phase 2 study that was terminated before completion, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 1 participants.
The verdict
NCT01715012, a Phase 2 study, was terminated before completion, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.
Interventions
- DRUG Saline
- BIOLOGICAL ST266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01715012
The ClinicalTrials.gov registry entry for NCT01715012 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01715012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01715012 about?
NCT01715012 is a clinical study titled "Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts". This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether t...
What is the current status of trial NCT01715012?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01715012?
The interventions under investigation include: Saline (DRUG), ST266 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01715012?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.